Evidence map›Paper›PMID 33108110›Full record

ArticleChronic obstructive pulmonary diseases (Miami, Fla.)2020

Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.

Robert M Burkes, Agathe S Ceppe, David J Couper, Alejandro P Comellas, J Michael Wells, Stephen P Peters, Gerard J Criner, Richard E Kanner, Robert Paine, Stephanie A Christenson and 10 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chronic obstructive pulmonary diseases (Miami, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969344 active not recruitingnot on this map

Subpopulations and Intermediate Outcome Measures in COPD Study

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2010 to 2031Enrolled2,981ConditionsCOPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Antimicrobial Peptides SLPI and Beta Defensin-1 in Sputum are Negatively Correlated with FEVInternational journal of chronic obstructive pulmonary disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Robert M BurkesDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill.
Agathe S CeppeMarsico Lung Institute, University of North Carolina, Chapel Hill.
David J CouperGillings School of Global Public Health, University of North Carolina, Chapel Hill.
Alejandro P ComellasDivision of Pulmonary, Critical Care, and Occupational Medicine, Carver College of Medicine, University of Iowa, Iowa City.
J Michael WellsDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama, Birmingham.
Stephen P PetersSection of Pulmonary, Critical Care, Allergy, and Immunologic Disease, Wake Forest University, Winston-Salem, North Carolina.
Gerard J CrinerDivision of Thoracic Medicine and Surgery, Temple University, Philadelphia, Pennsylvania.
Richard E KannerDivision of Respiratory, Critical Care and Occupational Pulmonary Medicine, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City.
Robert PaineDivision of Respiratory, Critical Care and Occupational Pulmonary Medicine, Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City.
Stephanie A ChristensonDivision of Pulmonary Critical Care, Allergy, and Sleep Medicine, University of California, San Francisco.
Christopher B CooperDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles.
Igor Z BarjaktarevicDivision of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles.
Jerry A KrishnanDivision of Pulmonary, Critical Care, Sleep, and Allergy Medicine, University of Illinois, Chicago.
Wassim W LabakiDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor.
MeiLan K HanDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor.
Jeffrey L CurtisDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor.
Nadia N HanselDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University Baltimore, Maryland.
Robert A WiseDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University Baltimore, Maryland.
M Bradley DrummondDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill.
SPIROMICS collaborators
University of Michigan–Ann Arbor · USJohns Hopkins University · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Illinois Urbana-Champaign · USUniversity of North Carolina at Chapel Hill · USWake Forest University · US

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPDR01HL125432 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DRUMMOND, MICHAEL BRADLEY · 2015 to 2019
$3.1M
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2M
Identifying the Th2 endotype in COPD: clinical and pathologic implicationsK23HL123778 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTENSON, STEPHANIE A · 2015 to 2019
$847k
Clinical Significance of the Antimicrobial Peptide Cathelicidin in Acute Exacerbations of COPDF32HL143867 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BURKES, ROBERT M · 2018 to 2019
$142k
Foundation for the National Institutes of HealthNHLBI NIH HHS F32 HL143867NHLBI NIH HHS F32HL143867NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K23 HL123778NHLBI NIH HHS K24 HL137013NHLBI NIH HHS R01 HL125432NHLBI NIH HHS R01HL125432-06NHLBI NIH HHS U01 HL137880NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

ratrionaleThe antimicrobial peptide cathelicidin, also known in humans as LL-37, is a defensin secreted by immune and airway epithelial cells. Deficiencies in this peptide may contribute to adverse pulmonary outcomes in chronic obstructive pulmonary disease (COPD).

objectivesUsing clinical and biological samples from the SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS), we assessed the associations of plasma cathelicidin levels with cross-sectional and longitudinal COPD outcomes.

methodsA total of 1609 SPIROMICS participants with COPD and available plasma samples were analyzed. Cathelicidin was modeled dichotomously (lowest quartile [< 50 ng/ml] versus highest 75% [≥ 50 ng/ml]) and continuously per 10 ng/ml. Fixed-effect multilevel regression analyses were used to assess associations between cathelicidin and cross-sectional as well as longitudinal lung function. The associations between cathelicidin and participant-reported retrospective and prospective COPD exacerbations were assessed via logistic regression. MEASUREMENTS AND MAIN

resultsCathelicidin < 50 ng/ml (N=383) was associated with female sex, black race, and lower body mass index (BMI).At baseline,cathelicidin < 50 ng/ml was independently associated with 3.55% lower % predicted forced expiratory volume in 1 second (FEV

conclusionsReduced cathelicidin is associated with lower lung function at baseline. Plasma cathelicidin may potentially identify COPD patients at increased risk for more severe lung disease.

Indexed as

cathelicidincopdCOPD outcomesimmunologyinnate immunity

Identifiers

PMID33108110
PMCPMC7883905
OpenAlexW3093694544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.